<DOC>
	<DOCNO>NCT02181530</DOCNO>
	<brief_summary>This study use retrospective data evaluate safety efficacy OZURDEX® ( dexamethasone intravitreal implant 0.7 mg ) treatment macular oedema due retinal vein occlusion ( RVO ) clinical practice . No intervention administer part study .</brief_summary>
	<brief_title>Retrospective Data Collection Study Patients With Macular Oedema Receiving OZURDEX®</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Macular oedema least one eye due branch retinal vein occlusion ( BRVO ) central vein occlusion ( CRVO ) Received least one injection OZURDEX® study eye</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>